Two other key regulators of the Hippo pathway, LATS2 and WWC1 (also called KIBRA), showed mutations in 6.5% and 4.9% of the cancers in the group with SOX2 suppression, which was higher than in the group with maintained SOX2 expression (2.1% and 3.1%, respectively) but without attaining statistical significance (Fisher’s exact test with p = 0.19 and 0.73, respectively, in Figure 3). This evidence concerns the gene LATS2 and cancer.